LARIMAR THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
LARIMAR THERAPEUTICS, INC. (LRMR) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 80.09 thousand shares for the 9-month period ending 2021-09-30, per its 10-Q filed 2021-11-12.
Discontinued › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2021-11-12
- LARIMAR THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2021-09-30 was 15.10K shares.
- LARIMAR THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2021-06-30 was 50.69K shares.
- LARIMAR THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2021-03-31 was 14.30K shares.
- LARIMAR THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2020-12-31 was 0.00 shares.
- LARIMAR THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2020 was 6.76K shares.
- LARIMAR THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2016 was 932.67K shares, a 2544.51% increase from fiscal 2015.
- LARIMAR THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2015 was 35.27K shares.
- LARIMAR THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2014 was 0.00 shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month |
|---|---|---|---|---|
| 2021-09-30 | 15.10K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | 65.79K shares derived: sum of 2 quarters · filed 2021-11-12 | 80.09K shares 10-Q · filed 2021-11-12 | 80.09K shares derived: sum of 4 quarters · filed 2021-11-12 |
| 2021-06-30 | 50.69K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | 64.99K shares 10-Q · filed 2021-08-12 | 64.99K shares derived: sum of 3 quarters · filed 2021-08-12 | |
| 2021-03-31 | 14.30K shares 10-Q · filed 2021-05-10 | 14.30K shares derived: sum of 2 quarters · filed 2021-05-10 | ||
| 2020-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-04 | 6.76K shares 10-K · filed 2021-03-04 | ||
| 2020-09-30 | 6.76K shares 10-Q · filed 2020-11-12 | |||
| 2019-09-30 | 2.17M shares 10-Q · filed 2019-11-06 | |||
| 2016-12-31 | 932.67K shares 10-K · filed 2017-03-10 | |||
| 2015-12-31 | 35.27K shares 10-K · filed 2016-03-15 | |||
| 2014-12-31 | 0.00 shares 10-K · filed 2015-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |